Shanghai Henlius Biotech refiles $500m IPO application

Reckitthealthcare_fotolia_230x150
By Gina Lee
08 Jul 2019

Shanghai Henlius Biotech has resubmitted its application to list on the Hong Kong Stock Exchange with an IPO worth around $500m.

The biotechnology company is being spun off by parent Shanghai Fosun Pharmaceutical Group.

The refiling last Friday came as the initial application filed with the HKEX in December 2018 lapsed. Shanghai Fosun had approved the spin-off at a board meeting three months earlier.

Shanghai ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial